TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Opdivo (Nivolumab)

Opdivo / Nivolumab. Used for selected cancers, including melanoma, lung and kidney cancer, under disease-specific conditions.

PMDAproduct-level source2026-09label updated2026-10-05site verified
オプジーボ点滴静注20mg/100mg/120mg/240mg · 100 mg / 10 mL
Japanese product photo · 100 mg / 10 mL · BMS Oncology Japan
Main useUsed for selected cancers, including melanoma, lung and kidney cancer, under disease-specific conditions.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
オプジーボ点滴静注20mg/100mg/120mg/240mg
Brand
Opdivo
Generic name
Nivolumab
Japanese generic name
ニボルマブ
Chinese name
纳武利尤单抗
Marketing authorization holder
小野薬品工業株式会社
Strengths
20 mg / 100 mg / 120 mg / 240 mg
Dosage form
IV infusion
Therapeutic area
Oncology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Opdivo is an anti-PD-1 immune-checkpoint antibody. Vial strength is different from total treatment dose.

Read source section ↗
02

Mechanism of action

Blocks PD-1 binding to PD-L1/PD-L2, restoring antitumor T-cell activity; normal organs may also be affected.

Read source section ↗
03

Japanese indications & eligibility

Japanese labeling covers multiple selected cancers. Stage, prior therapy, biomarkers and combination requirements differ by indication.

Read source section ↗
04

Administration & dose differences

Some adult monotherapy regimens use 240 mg every two weeks or 480 mg every four weeks; combinations and pediatric regimens differ.

Read source section ↗
05

Adverse effects & key risks

Important risks include pneumonitis, colitis, hepatitis, endocrine disease, nephritis, myocarditis and infusion reactions.

Read source section ↗
06

Contraindications & special populations

Ingredient hypersensitivity is contraindicated. Review autoimmune disease, transplantation, lung disease, infection and pregnancy.

Read source section ↗
07

Drug interactions

Combination toxicity and immunosuppressive medicines require oncology review.

Read source section ↗
08

Assessment & monitoring

Monitor blood counts, liver/kidney function, glucose, thyroid function and clinically indicated imaging.

Read source section ↗
09

Storage & handling

Refrigerate unopened vials at 2–8°C, protect from light and do not freeze. Preparation is for clinical staff.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.